Program
tersolisib
Also written as “LY4064809”, “Tersolisib” and “STX-478”.
Its studies are mostly in Breast Neoplasms · Renal Insufficiency, led by Eli Lilly.
Furthest: phase 3, since Sep 12, 202510 company-led studies, 4 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 104 open or running | phase 3since Sep 12, 2025 | Mar 1, 2023 | Aug 2027phase 1 · NCT07924930 |
- Named in Eli Lilly’s own pipeline as
Tersolisib
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2023First study: phase 2 study in Breast NeoplasmsFirst studyNCT05768139 · 880 planned · United States, Belgium, France and more
- Mar 24, 2025Phase 1 study in HealthyNCT06901336 · 8 enrolled · United States
- May 19, 2025Phase 1 study in HealthyNCT06991179 · 36 enrolled · United States
- Sep 12, 2025Phase 3 study in Breast NeoplasmsNCT07174336 · 800 planned · United States, Argentina, Australia and more
- Nov 18, 2025Phase 1 study in HealthyNCT07247357 · 10 enrolled · Singapore
- Jan 6, 2026Phase 1 study in Healthy ParticipantsNCT07339735 · 24 enrolled · United States
- Mar 30, 2026Phase 1 study in HealthyNCT07519525 · 7 enrolled · United States
- Jun 17, 2026Phase 1 study in HealthyNCT07662798 · 60 enrolled · United States
- Nov 4, 2026Phase 1 study in Renal InsufficiencyNCT07924930 · 32 planned · United States
- Nov 9, 2026Phase 2 study in Breast NeoplasmsNCT07935317 · 120 planned · United States
Ahead
- Aug 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07924930
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07935317
- May 2029Primary completion: phase 3 study in Breast NeoplasmsNCT07174336
- Jul 2030Primary completion: phase 2 study in Breast NeoplasmsNCT05768139
TargetBeta
“An orally bioavailable, brain penetrative, selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha) mutant H1047X, with potential antineoplastic activity. Upon oral administration, te…”NCIt, read by Claude
“An orally bioavailable, brain penetrative, selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha) mutant H1047X, ”NCIt, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07935317Breast Neoplasms · United States | 2 | Not yet recruiting | Dec 2027 | 120 |
| NCT07924930Renal Insufficiency · United States | 1 | Not yet recruiting | Aug 2027 | 32 |
| NCT07662798Healthy · United States | 1 | Completed | Sep 3, 2026 | 60 |
| NCT07519525Healthy · United States | 1 | Completed | May 26, 2026 | 7 |
| NCT07339735Healthy Participants · United States | 1 | Completed | Mar 19, 2026 | 24 |
| NCT07247357Healthy · Singapore | 1 | Completed | Dec 16, 2025 | 10 |
| NCT07174336Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | May 2029 | 800 |
| NCT06991179Healthy · United States | 1 | Completed | Sep 2, 2025 | 36 |
| NCT06901336Healthy · United States | 1 | Completed | May 6, 2025 | 8 |
| NCT05768139Breast Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Jul 2030 | 880 |
How it is read
Names in the registry
- “LY4064809”, 4 entries
- “Tersolisib”, 3 entries
- “STX-478”, 1 entry
- “LY4064809 Test Formulation”, 1 entry
- “LY4064809 Reference Formulation”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.